Yun Yen - Jun 30, 2022 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Yun Yen
Stock symbol
LIXT
Transactions as of
Jun 30, 2022
Transactions value $
$0
Form type
4
Date filed
8/3/2022, 04:47 PM
Previous filing
May 20, 2022
Next filing
Jul 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +100K $0.00 100K Jun 30, 2022 Common 100K $0.74 Direct F1
holding LIXT Options to Purchase Common Stock 100K Jun 30, 2022 Common 100K $3.03 Direct
holding LIXT Options to Purchase Common Stock 50K Jun 30, 2022 Common 50K $3.21 Direct
holding LIXT Warrants to Purchase Common Stock 52.6K Jun 30, 2022 Common 52.6K $5.70 By Sino-American Cancer FDD
holding LIXT Options to Purchase Common Stock 33.3K Jun 30, 2022 Common 33.3K $1.68 Direct
holding LIXT Options to Purchase Common Stock 8.33K Jun 30, 2022 Common 8.33K $6.60 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective June 30, 2022, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2022).